Upwell Health Appoints Patrick Grosso to Lead Finances
Upwell Health, the company that makes pharmacy the central point of care for people with chronic conditions by educating, empowering, and simplifying life, promotes Patrick Grosso to Chief Financial Officer. Grosso has served Upwell as Chief Administrative Officer since March 2018 and interim CFO since November. He will now be responsible for all finance, accounting, legal, compliance, procurement, and supply chain activities as well as developing strategic initiatives and financial plans that help the company achieve greater efficiencies through an upgraded technology platform.
“Chronic conditions can take a significant toll on both patients and caregivers. Since joining Upwell, I’ve been inspired by the work we do on a daily basis to get members the care and resources they need to live healthier, more empowered lives,” said Grosso in a statement. “I can’t imagine a time of more exciting, energizing market opportunity for the company, and I’m honored to be a part of it.” Grosso boasts more than 20 years of private and public operations experience, including a prior position as Skullcandy’s Vice President of Strategic Initiatives and Corporate Affairs.
Sanofi Names Dr. Ameet Nathwani Chief Digital Officer
The pharma giant appoints Ameet Nathwani, MD as Chief Digital Officer in addition to his current role of Executive Vice President, Chief Medical Officer—a position he has held since joining the team in May 2016. The digital health expert is charged with enhancing Sanofi’s strategy to integrate digital technologies and medical science to improve patient outcomes. He is expected to scale up Sanofi’s portfolio of digital initiatives by developing broad external partnerships, building out internal infrastructures, and exploring new business opportunities for Sanofi in the digital space.
Olivier Brandicourt, Chief Executive Officer at Sanofi, in a statement said, “With Ameet’s wide experience in digital health and analytics, we will be able to further advance our capabilities to re-invent not only the way we discover and develop medicines but the types of future products we may offer to patients around the world.”
The neuroscience company formed by Bain Capital and Pfizer brings on Raymond Sanchez, MD, as its new Chief Medical Officer. Dr. Sanchez comes from an 11-year pharmaceutical development and commercialization role at Otsuka to lead development of Cerevel’s late-stage programs for Parkinson’s disease and epilepsy.
The company with a mission to support clinical research and studies across the pharmaceutical, biopharma, academic, and healthcare landscape has formed a new Science Advisor Panel comprised of renowned scientists and technologists, including Alex “Sandy” Pentland, PhD and Nicholas Fortugno. Dr. Pentland directs the MIT Connection Science and Human Dynamics labs and previously helped create the MIT Media Lab. He is one of the most-cited scientists in the world, Forbes having recently declared him one of the “seven most powerful data scientists in the world.” Fortugno is a design expert and Chief Creative Officer of Playmatics, a company that creates highly engaging games, media, user experiences, and applications on the internet and social media networks.
Dr. Reddy’s Laboratories
The integrated pharmaceutical company names Marc Kikuchi as Chief Executive Officer,
North America Generics. Kikuchi offers more than 20 years of experience in generics, joining Dr. Reddy’s from Zydus Pharmaceuticals, Inc. where he served as CEO, Americas since 2016. Operating from the Princeton base, Kikuchi will be responsible for the North American business plan.
The rare diseases biopharma leader names industry veteran Rachelle Jacques CEO as it prepares for the potential commercialization of the company’s first therapy. Jacques joins Enzyvant from Alexion where she served as Senior Vice President and Global Franchise Head of Complement. Prior to this, Jacques was Vice President of U.S. Hematology Marketing at Shire and Baxalta.
Hanzhong Li, PhD, MBA is appointed to Senior Vice President of Corporate Development at the clinical-stage biotechnology company developing T-cell therapies. Dr. Li will call upon his 20 years of experience, including his time as Deputy Director in strategy and portfolio management at Bayer Pharmaceuticals, to help Eureka grow.
FCB Health Network
The communications network creates the role of Senior Vice President and Director of Product Design for Chris Seda. He will build and lead the Network’s new digital product design practice, which will offer a wide breadth of digital expertise, including web, mobile, apps, voice, and experiential product design. The digital expert comes from Dentsu 360i, where he led experience design and product design capabilities.
Trey Watkins joins the healthcare communications agency as Senior Vice President, leading the agency’s global health and corporate responsibility work along with Margaret Shubny, who joins as Executive Vice President to grow the company’s corporate communications offering. Watkins will use his experience in global health governance to counsel some of the world’s most influential partners in their efforts to strengthen health systems, increase access to medicines and services, and provide sustainable solutions to global health challenges. Shubny will be responsible for providing strategic insights, counsel, and services for corporate communications to advance reputational value and market leadership.
The biotech appoints Robert Friesen, PhD as Chief Scientific Officer to lead the company’s science, discovery, and preclinical development activities as well as build the scientific platform and identify other programs for potential in-license. Dr. Friesen has more than 20 years of experience in the biopharmaceutical industry, leading R&D at multiple organizations, including Ablynx, ProQR Therapeutics, and Janssen BioTherapeutics.
Lighthouse Medical Communications
The U.S. division of Lighthouse taps Lisa Druce, Ashfield Healthcare Communications’ former Senior Vice President, Commercial Expansion and Operations, as their new Managing Partner. Druce is an expert in leading strategic growth and innovation initiatives and will be expected to expand the agency’s presence in the U.S. as they grow and continue to improve patients’ lives.
Amidst its rebranding, the respiratory monitoring company names prominent pulmonologist Richard Murray, MD as Chief Medical Officer to help lead its remote patient monitoring product development, healthcare partnerships, and clinical trials. Dr. Murray joins Spire Health from Merck, where he served as Deputy Chief Medical Officer.